| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
Purity: ≥98%
Azido-PEG3-alcohol is a PEG analogue containing an azide group and a terminal hydroxyl group. The hydrophilic PEG spacer increases solubility in aqueous media. The azide group can react with alkyne, BCN, DBCO via Click Chemistry to yield a stable triazole linkage. The hydroxyl group enables further derivatization or replacement with other reactive functional groups.
| Targets |
This molecule has no intrinsic biological target. Its function is as a hydrophilic spacer arm for joining two pharmacologically active molecules. In PROTACs, it serves as a linker to connect a ligand for a target protein with a ligand for an E3 ubiquitin ligase, thereby enabling the selective degradation of disease-relevant proteins via the ubiquitin-proteasome system.
|
|---|---|
| ln Vitro |
One ligand is for an E3 ubiquitin ligase, and the other is for the target protein; these two ligands are joined by a linker to form PROTACs. The intracellular ubiquitin-proteasome system is utilized by PROTACs to specifically destroy target proteins[1].
As a standalone compound, Azido-PEG3-alcohol is chemically inert in most biological assays. Its utility is realized after conjugation to other molecules via click chemistry (CuAAc or SPAAC). Its hydrophilic PEG3 chain increases the water solubility and reduces the steric hindrance of the final conjugated product, which is a key property for successful in vitro experiments involving biomolecules. |
| ln Vivo |
The compound itself is not administered as a therapeutic. When incorporated as a linker into a larger molecule, the PEG3 spacer contributes to the conjugate‘s overall pharmacokinetic profile. It is generally considered to help improve the conjugate’s aqueous solubility and potentially prolong its circulation time by reducing immunogenicity and aggregation, which are highly beneficial properties for the in vivo performance of therapeutic candidates.
|
| Enzyme Assay |
Being a linker, it has no specific receptor-binding activity. It is used for the chemical synthesis of protein-binding probes. A typical protocol involves the conjugation of Azido-PEG3-alcohol to an alkyne-modified molecule via copper-catalyzed azide-alkyne cycloaddition.
|
| Cell Assay |
This compound is not assayed for cellular activity by itself. It is used to synthesize cell-active molecules like PROTACs. Cells are then treated with the final PROTAC compound, and protein degradation is measured by immunoblotting (Western blot) or other cellular assays to evaluate the efficacy of the molecule that the linker helped create.
|
| Animal Protocol |
No direct animal testing is performed on this linker itself. Instead, the final PROTAC or conjugate molecule is formulated and administered to animals (e.g., mice or rats) via routes such as intravenous, intraperitoneal, or oral gavage, typically after dissolution in vehicles like 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline. Plasma concentrations are then measured to assess the drug’s pharmacokinetics.
|
| ADME/Pharmacokinetics |
PK properties are dictated by the final PROTAC or conjugate molecule, not by the PEG linker alone. However, the incorporation of a PEG3 spacer is a well-established strategy to improve the aqueous solubility and stability of the parent molecule. This modification can positively influence bioavailability and reduce immunogenicity, thereby contributing to favorable PK profiles in drug development.
|
| Toxicity/Toxicokinetics |
Azido-PEG3-alcohol is classified as a laboratory research chemical. Safety data sheets indicate that it is toxic and a known skin and eye irritant. It is not approved for human use and should be handled only by trained personnel using appropriate protective equipment.
|
| References |
| Molecular Formula |
C6H13N3O3
|
|---|---|
| Molecular Weight |
175.18572
|
| Exact Mass |
175.096
|
| CAS # |
86520-52-7
|
| Related CAS # |
86520-52-7;
|
| PubChem CID |
11008438
|
| Appearance |
Colorless to light yellow liquid
|
| Flash Point |
-33℃
|
| LogP |
0.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
12
|
| Complexity |
136
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[N-]=[N+]=NCCOCCOCCO
|
| InChi Key |
PMNIHDBMMDOUPD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H13N3O3/c7-9-8-1-3-11-5-6-12-4-2-10/h10H,1-6H2
|
| Chemical Name |
2-[2-(2-azidoethoxy)ethoxy]ethanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~570.81 mM)
H2O : ~100 mg/mL (~570.81 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.27 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.27 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.27 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (570.81 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7081 mL | 28.5404 mL | 57.0809 mL | |
| 5 mM | 1.1416 mL | 5.7081 mL | 11.4162 mL | |
| 10 mM | 0.5708 mL | 2.8540 mL | 5.7081 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA